Table 2

Characteristics of breast primary in study population
Number of patients (%)
Stage at diagnosis
  1 20 (17.2)
  2 52 (44.8)
  3 30 (25.9)
  4 14 (12.2)
Grade
  1 8 (6.9)
  2 51 (44)
  3 57 (49.1)
Nodal status
  Negative 23 (19.8)
  Positive 93 (80.2)
HR status
  ER and/or PR positive 74 (63.8)
  ER and PR negative 42 (36.2)
HER2 status
  Negative 79 (68.1%)
  Positive 37 (31.8%)
Neoadjuvant or Adjuvant treatment
  Nil or non-compliant 14 (13.7)
  Endocrine only 6 (5.9)
  Non-anthracycline chemotherapy 11 (10.8)
  Anthracycline-base chemotherapy 38 (37.3)
  Anthracycline and taxane 29 (28.4)
  Taxane only 4 (3.9)
Adjuvant trastuzumab 10 (8.6)
Disease-free interval, median (range) 36.3 (26.2 – 135)

Chan et al.

Chan et al. BMC Cancer 2012 12:555   doi:10.1186/1471-2407-12-555

Open Data